Literature DB >> 8469238

Mullerian inhibiting substance requires its N-terminal domain for maintenance of biological activity, a novel finding within the transforming growth factor-beta superfamily.

C A Wilson1, N di Clemente, C Ehrenfels, R B Pepinsky, N Josso, B Vigier, R L Cate.   

Abstract

Mullerian inhibiting substance (MIS)/anti-Mullerian hormone is a differentiation factor that causes regression of the Mullerian duct in the developing male fetus and an apparent sex reversal of the fetal ovary when inappropriately exposed to it. The purified product is a 140-kilodalton glycoprotein composed of two identical subunits. We show that a C-terminal fragment of MIS, which shares homology with transforming growth factor-beta, causes regression of the Mullerian duct and inhibits the biosynthesis of aromatase in the fetal ovary. However, both activities are enhanced dramatically by addition of the N-terminal portion of MIS. Under conditions where potentiation occurs, the N- and C-terminal domains of MIS reassociate. These results indicate that the N-terminus of MIS, unlike that of the other members of the transforming growth factor-beta family, plays a role in maintaining the biological activity of the C-terminus.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8469238     DOI: 10.1210/mend.7.2.8469238

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  23 in total

1.  Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-beta.

Authors:  Nathalie di Clemente; Soazik P Jamin; Alexey Lugovskoy; Paul Carmillo; Christian Ehrenfels; Jean-Yves Picard; Adrian Whitty; Nathalie Josso; R Blake Pepinsky; Richard L Cate
Journal:  Mol Endocrinol       Date:  2010-09-22

2.  Latent TGF-β structure and activation.

Authors:  Minlong Shi; Jianghai Zhu; Rui Wang; Xing Chen; Lizhi Mi; Thomas Walz; Timothy A Springer
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

Review 3.  Emerging Roles of Anti-Müllerian Hormone in Hypothalamic-Pituitary Function.

Authors:  Anne-Laure Barbotin; Maëliss Peigné; Samuel Andrew Malone; Paolo Giacobini
Journal:  Neuroendocrinology       Date:  2019-07-05       Impact factor: 4.914

Review 4.  Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

Authors:  David T MacLaughlin; Patricia K Donahoe
Journal:  Future Oncol       Date:  2010-03       Impact factor: 3.404

5.  Bioactivation of Müllerian inhibiting substance during gonadal development by a kex2/subtilisin-like endoprotease.

Authors:  M W Nachtigal; H A Ingraham
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

Review 6.  Anti-Müllerian Hormone Signal Transduction involved in Müllerian Duct Regression.

Authors:  Richard L Cate
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

7.  Intrafollicular antimüllerian hormone levels predict follicle responsiveness to follicle-stimulating hormone (FSH) in normoandrogenic ovulatory women undergoing gonadotropin releasing-hormone analog/recombinant human FSH therapy for in vitro fertilization and embryo transfer.

Authors:  Daniel A Dumesic; Timothy G Lesnick; Jacques P Stassart; G David Ball; Ashley Wong; David H Abbott
Journal:  Fertil Steril       Date:  2009-07       Impact factor: 7.329

8.  The anti-Müllerian hormone type II receptor: insights into the binding domains recognized by a monoclonal antibody and the natural ligand.

Authors:  Imed Salhi; Sylvie Cambon-Roques; Isabelle Lamarre; Daniel Laune; Franck Molina; Martine Pugnière; Didier Pourquier; Marian Gutowski; Jean-Yves Picard; Françoise Xavier; André Pèlegrin; Isabelle Navarro-Teulon
Journal:  Biochem J       Date:  2004-05-01       Impact factor: 3.857

Review 9.  TGF-β and the TGF-β Family: Context-Dependent Roles in Cell and Tissue Physiology.

Authors:  Masato Morikawa; Rik Derynck; Kohei Miyazono
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-05-02       Impact factor: 10.005

10.  Anti-Müllerian hormone concentration regulates activin receptor-like kinase-2/3 expression levels with opposing effects on ovarian cancer cell survival.

Authors:  Maëva Chauvin; Véronique Garambois; Sylvie Choblet; Pierre-Emmanuel Colombo; Myriam Chentouf; Laurent Gros; David-Paul De Brauwere; Martine Duonor-Cerutti; Karen Dumas; Bruno Robert; Marta Jarlier; Pierre Martineau; Isabelle Navarro-Teulon; David Pépin; Thierry Chardès; André Pèlegrin
Journal:  Int J Oncol       Date:  2021-05-20       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.